PT - JOURNAL ARTICLE AU - Yan, Qihong AU - Li, Pingchao AU - Ye, Xianmiao AU - Huang, Xiaohan AU - Mo, Xiaoneng AU - Wang, Qian AU - Zhang, Yudi AU - Luo, Kun AU - Chen, Zhaoming AU - Luo, Jia AU - Niu, Xuefeng AU - Feng, Ying AU - Ji, Tianxing AU - Feng, Bo AU - Wang, Jinlin AU - Li, Feng AU - Zhang, Fuchun AU - Li, Fang AU - Wang, Jianhua AU - Feng, Liqiang AU - Chen, Zhilong AU - Lei, Chunliang AU - Qu, Linbing AU - Chen, Ling TI - Longitudinal peripheral blood transcriptional analysis of COVID-19 patients captures disease progression and reveals potential biomarkers AID - 10.1101/2020.05.05.20091355 DP - 2020 Jan 01 TA - medRxiv PG - 2020.05.05.20091355 4099 - http://medrxiv.org/content/early/2020/05/08/2020.05.05.20091355.short 4100 - http://medrxiv.org/content/early/2020/05/08/2020.05.05.20091355.full AB - COVID-19, caused by SARS-CoV-2, is an acute self-resolving disease in most of the patients, but some patients can develop a severe illness or even death. To characterize the host responses and identify potential biomarkers during disease progression, we performed a longitudinal transcriptome analysis for peripheral blood mononuclear cells (PBMCs) collected from 4 COVID-19 patients at 4 different time points from symptom onset to recovery. We found that PBMCs at different COVID-19 disease stages exhibited unique transcriptome characteristics. SARS-CoV-2 infection dysregulated innate immunity especially type I interferon response as well as the disturbed release of inflammatory cytokines and lipid mediators, and an aberrant increase of low-density neutrophils may cause tissue damage. Activation of cell death, exhaustion and migratory pathways may lead to the reduction of lymphocytes and dysfunction of adaptive immunity. COVID-19 induced hypoxia may exacerbate disorders in blood coagulation. Based on our analysis, we proposed a set of potential biomarkers for monitoring disease progression and predicting the risk of severity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the National Natural Science Foundation of China (82041014 and 81661148056), the Chinese Academy of Sciences Pilot Strategic Science and Technology Projects (XDB29050701).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll raw RNA-seq data used in this study have been deposited at the National Genomics Data Center (https://bigd.big.ac.cn/) under the accession number: PRJCA002599. All scripts used in this study are publicly available at https://github.com/ChenLinglab/.